DCGI approves KEYTRUDA to treat triple negative breast cancer, renal cell carcinoma

KEYTRUDA is now approved for 14 indications across eight tumour types in India

MSD (known as Merck in US and Canada) announced that the Drug Controller General of India (DCGI) has approved KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy, for the treatment of triple-negative breast cancer and renal cell carcinoma in adults. KEYTRUDA has been approved for high-risk early-stage and metastatic triple-negative breast cancer for select patients who are at a high risk of recurrence.

With this approval, KEYTRUDA is now the first immunotherapy approved for the adjuvant treatment of certain patients with renal cell carcinoma and early stage triple-negative breast cancer.

Keytruda is an immunotherapy that works with the immune system to help fight cancer cells. It is different from chemotherapy or radiation therapy. The immune system sends certain types of cells called T-cells throughout your body to detect and fight infections and diseases—including cancer. Cancer cells may use the PD-1 pathway to hide from T-cells. This stops T-cells from attacking cancer cells and allows cancer cells to grow and spread. KEYTRUDA blocks the PD-1 pathway to help prevent cancer cells from hiding. KEYTRUDA helps the immune system to detect and fight cancer cells.

Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer, which has the highest risk of recurrence within the first five years after diagnosis and is associated with worse outcomes compared to other forms of breast cancer.

Renal cell carcinoma is by far the most common type of kidney cancer. Renal cell carcinoma is about twice as common in men than in women. Despite decades of research, limited treatment options are available for treatment of renal cell carcinoma who are often at risk of recurrence. This approval will address a critical unmet need for select patients.

DCGIimmunotherapyKeytrudaMerckMSD Indiaoncologyrenal cell carcinomatriple-negative breast cancer
Comments (0)
Add Comment